Kalyan Roy: Asundexian Approval Marks a Milestone in Targeted Anticoagulation
Kalyan Roy, Specialist Transfusion Medicine Center at Square Hospitals LTD, shared a post on LinkedIn:
“A new era in anticoagulation? Can we prevent blood clots without increasing bleeding risk?
A significant milestone in cardiovascular medicine!
On November 9, 2026, the US FDA approved Asundexian (SUNHARBO®), developed by Bayer — the first approved drug in a new class of anticoagulants known as Factor XIa inhibitors.
What makes it different?
Unlike conventional anticoagulants that target Factor Xa or thrombin, Asundexian selectively inhibits activated Factor XI (FXIa), an important component of the intrinsic coagulation pathway.
The goal?
To prevent pathological thrombosis while preserving more of the body’s natural haemostatic response.
Oceanic-Stroke: Key clinical findings
A landmark Phase III trial involving 12,327 patients demonstrated:
- 26 percent lower relative risk of recurrent ischemic stroke.
- Recurrent ischemic stroke: 6.2 percent with Asundexian versus 8.4 percent with placebo.
- Major bleeding: 1.9 percent versus 1.7 percent, with no statistically significant difference.
- Treatment: 50 mg orally once daily, alongside standard antiplatelet therapy.
Important clinical considerations
- Asundexian reduces stroke risk; it does not eliminate it.
- Gastrointestinal bleeding remains an important safety consideration.
- It is not approved as a replacement for conventional anticoagulation in atrial fibrillation.
- The findings apply to the specific non-cardioembolic stroke prevention population studied.
Why does this matter?
For decades, clinicians have faced a difficult balance between preventing thrombosis and increasing bleeding risk.
Factor XIa inhibition represents a promising approach to achieving more selective antithrombotic protection.
The future of anticoagulation may not simply be about stronger blood thinners — but smarter and more targeted inhibition of coagulation.
A fascinating development for clinicians, haematologists, cardiologists and transfusion medicine specialists!
Key Reference: Sharma M, et al. OCEANIC-STROKE. The New England Journal of Medicine, 2026.”
Other posts featuring Kalyan Roy on Hemostasis Today.
-
Nov 14, 2026, 23:32Julia Pitcher: Strengthening Legislative Efforts for the Sickle Cell and Thalassemia Community
-
Nov 14, 2026, 23:31Sidi Mohamed El Amine Benlazar: The Role of Cytoreductive Therapy in MPN-Associated Splanchnic Vein Thrombosis
-
Nov 14, 2026, 23:24Roxana González: Pathogenesis of Vascular Disease in Behcet’s Syndrome
-
Nov 14, 2026, 23:15Pierre Sabouret: Despite the NEJM Publication, I Still Prefer DOACs
-
Nov 14, 2026, 16:35Sultan Aydın Aslantaş: A Rare Coexistence of LAHPS and Bloom Syndrome in a Child
-
Nov 14, 2026, 16:27Nicolas Moniotte: Dual-Platform Gene Editing for Haemophilia A
-
Nov 14, 2026, 15:30Patient Selection for Gene Therapy in Transfusion-Dependent β-Thalassemia – EHA
-
Nov 14, 2026, 15:07Vaidehi Prasanth: Patient Blood Management in Hematological Patients A New Book Chapter
-
Nov 14, 2026, 15:00Ram Mohan Jaiswal: International Collaboration in Transfusion Medicine Through the Trans Med Africa Consortium